Background: Our study aims to identify baseline prognostic factors in metastatic castration resistant prostate cancer (mCRPC) patients treated with Radium-223. Methods: Data about demographics, ECOG performance status, lymph node (LN) involvement, local treatment for prostate cancer, previous systemic treatments, cells blood count, PSA, ALP, albumin, LDH, bone protecting agents use (BPA), analgesic use and survival were collected. Univariable and multivariable analyses were performed. Results: Seventy-five men received Radium-223 between September 2013 and December 2019. Median age was 73 years. Thirty-four (45.3%) had ECOG PS 0, 41 (54.7%) PS 1-2. In univariable analysis, LN involvement (HR 1.68, 95% CI 1.01-2.80, p=0.047), absence of local treatment on primary tumor (HR 1.93, 95% CI 1.13-3.29, p=0.016), baseline strong opioidsuse (HR 1.82, 95% CI 1.08-3.06, p=0.024), high platelets to lymphocyte ratio (PLR) (HR 1.91, 95% CI 1.06-3.45, p=0.03), high baseline ALP (HR 1.81, 95% CI 1.10-2.99, p=0.019) and high baseline LDH (HR 3.86,95% CI 2.01-7.41, p<0.001) were significantly associated with worst OS. At multivariable analysis, LN involvement, strong opioids use, baseline ALP, LDH and PLR levels were significantly associated with outcome. Conclusions: In mCRPC patients treated with Radium-223, baseline ALP, LDH, strong opioid use, PLR, LN involvement and treatment on primary site are associated with different OS.
Prognostic factors in metastatic castration resistant prostate cancer patients treated with Radium-223: a retrospective study
DI Stefano, Rosario F;Parente, Antonella;Bungaro, Maristella;Turco, Fabio;Samuelly, Alessandro;Pisano, Chiara;Scagliotti, Giorgio V;DI Maio, Massimo;Tucci, Marcello;Buttigliero, Consuelo
2022-01-01
Abstract
Background: Our study aims to identify baseline prognostic factors in metastatic castration resistant prostate cancer (mCRPC) patients treated with Radium-223. Methods: Data about demographics, ECOG performance status, lymph node (LN) involvement, local treatment for prostate cancer, previous systemic treatments, cells blood count, PSA, ALP, albumin, LDH, bone protecting agents use (BPA), analgesic use and survival were collected. Univariable and multivariable analyses were performed. Results: Seventy-five men received Radium-223 between September 2013 and December 2019. Median age was 73 years. Thirty-four (45.3%) had ECOG PS 0, 41 (54.7%) PS 1-2. In univariable analysis, LN involvement (HR 1.68, 95% CI 1.01-2.80, p=0.047), absence of local treatment on primary tumor (HR 1.93, 95% CI 1.13-3.29, p=0.016), baseline strong opioidsuse (HR 1.82, 95% CI 1.08-3.06, p=0.024), high platelets to lymphocyte ratio (PLR) (HR 1.91, 95% CI 1.06-3.45, p=0.03), high baseline ALP (HR 1.81, 95% CI 1.10-2.99, p=0.019) and high baseline LDH (HR 3.86,95% CI 2.01-7.41, p<0.001) were significantly associated with worst OS. At multivariable analysis, LN involvement, strong opioids use, baseline ALP, LDH and PLR levels were significantly associated with outcome. Conclusions: In mCRPC patients treated with Radium-223, baseline ALP, LDH, strong opioid use, PLR, LN involvement and treatment on primary site are associated with different OS.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
